Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy Pipeline and Next-Generation Vectors based on its AAV-Ligand Conjugate Platform
Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy Pipeline and Next-Generation Vectors based on its AAV-Ligand Conjugate Platform · Coave Therapeutics is the new name for Horama and reflects its new emphasis on AAV-Ligand Conjugate based vectors for CNS diseases alongside Ocular diseases · Funding led by Seroba […]
Read Post
Immunic, Inc. Announces Closing of $45.0 Million Public Offering
Immunic, Inc. Announces Closing of $45.0 Million Public Offering NEW YORK, July 19, 2021 /PRNewswire/ — Immunic, Inc. (the “Company”) (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the closing of an underwritten public offering of 4,500,000 shares of […]
Read Post
ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments
ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments Accelerated clinical development of ExeVir’s novel llama-derived antibody therapies for potential treatment and prevention of Covid-19 Manufacturing of ExeVir’s candidate product at Mithra CDMO’s new Injectable Facility Joint unique expertise of two Belgian biotechs to provide global access to innovative therapies for a broad range […]
Read Post
eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement
eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement Novel lipid nanoparticles for mRNA delivery will enhance thermostability, biodegradability and safety and pave the way for new off-the-shelf therapies Niel and Ghent (Belgium) eTheRNA immunotherapies NV (‘eTheRNA’), a clinical-stage company developing mRNA immunotherapies for the treatment of cancer and infectious diseases, announces […]
Read Post
ExeVir’s COVID-19 antibody candidate neutralizes coronavirus Variants of Concern
ExeVir’s COVID-19 antibody candidate neutralizes coronavirus Variants of Concern Data illustrates potent neutralization activity against the Gamma and Delta Variants of SARS-CoV-2 Receives EUR3 million grant to accelerate clinical development Exevir one step closer in development of ‘pan-coronavirus’ nanobodies Belgium, July 13, 2021: ExeVir, which is developing single domain antibody therapies providing broad protection against […]
Read Post
Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis
Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis – Phase 3 ENSURE Program in Relapsing-Remitting Multiple Sclerosis (RRMS) Comprises Twin Studies Evaluating Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo, Intended to Provide Straightforward Path to Regulatory […]
Read Post
eTheRNA immunotherapies and Quantoom Biosciences Announce a Strategic Collaboration for the Development of a Novel RNA Production System
eTheRNA immunotherapies and Quantoom Biosciences Announce a Strategic Collaboration for the Development of a Novel RNA Production System · The objective is to make RNA therapeutics accessible to global patient populations. · Makes large scale decentralized RNA production economically viable. 29 June 2021 | Niel and Brussels (Belgium) eTheRNA immunotherapies NV (‘eTheRNA’), a […]
Read Post
eTheRNA and VUB expand strategic collaboration to engineer next generation mRNA therapeutics with TetraMix®
eTheRNA and VUB expand strategic collaboration to engineer next generation mRNA therapeutics with TetraMix® Extension to proven TriMix® adjuvant technology intended to boost dendritic cell activation eTheRNA immunotherapies NV (‘eTheRNA’, Niel, Belgium), a clinical-stage company developing mRNA-based immunotherapies for the treatment of cancer and infectious diseases, announces the expansion of its strategic collaboration with Vrije […]
Read Post
Novadip Biosciences reports positive data from phase I study of NVD-001 for spinal fusion
Novadip Biosciences reports positive data from phase I study of NVD-001 for spinal fusion – Primary endpoint met, study validates autologous cell therapy 3M³ platform for bone regeneration and demonstrates manufacturing capabilities – Next generation autologous product NVD-003 to be advanced in clinical development Mont-Saint-Guibert, June 15, 2021 – Novadip Biosciences (“Novadip”), a clinical stage […]
Read Post
Confo Therapeutics Establishes Medical Advisory Board
Confo Therapeutics Establishes Medical Advisory Board Ghent, Belgium – June 10, 2021 – Confo Therapeutics today announced the establishment of its Medical Advisory Board (MAB). The MAB will provide external review and strategic advice for the company’s clinical development program including the future direction of CFTX-1554, Confo’s lead pre-clinical candidate in neuropathic pain. The […]
Read Post
Minoryx publishes mechanism of action of leriglitazone in X-ALD in Science Translational Medicine journal
Minoryx publishes mechanism of action of leriglitazone in X-ALD in Science Translational Medicine journal Published data highlights therapeutic potential for all forms of X-ALD as well as other neurodegenerative and neuroinflammatory diseases Mataró, Barcelona, Spain, June 3, 2021 – Minoryx Therapeutics, a Phase 3 clinical stage biotech company focused on the development of differentiating treatment […]
Read Post
Indigo Diabetes Appoints Paul Moraviec as Chairman of the Board
Indigo Diabetes Appoints Paul Moraviec as Chairman of the Board • Brings decades of leadership experience in the Global MedTech sector • As CEO of ConvaTec Group Plc, led the $4.5 billion IPO on the London Stock Exchange • Transformed Abbott’s Diabetes Care EMEA division BELGIUM – Ghent, May 12, 2021 – Indigo Diabetes N.V. […]
Read Post
Minoryx Phase 2/3 ‘ADVANCE’ study results to be presented at the 2021 American Neurological Association (AAN) Annual Meeting
Minoryx Phase 2/3 ‘ADVANCE’ study results to be presented at the 2021 American Neurological Association (AAN) Annual Meeting Additional clinical data will show benefits of leriglitazone in adrenomyeloneuropathy (AMN) Mataró, Barcelona, Spain, April 12, 2021 – Minoryx Therapeutics, a Phase 3 clinical stage biotech company focused on the development of differentiating treatment options in orphan […]
Read Post
Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic’s Lead Program, IMU-838
Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic’s Lead Program, IMU-838 NEW YORK and PLANEGG-MARTINSRIED, Germany, March 31, 2021 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, and 4SC AG (FSE Prime […]
Read Post
Michel Detheux (iTeos): ‘Biotech is als Formule 1: hoe meer geld, hoe sneller je kan gaan’
Michel Detheux (iTeos): ‘Biotech is als Formule 1: hoe meer geld, hoe sneller je kan gaan’ Michel Detheux: ‘We hebben voor de agressieve aanpak gekozen en 210 miljoen dollar opgehaald op Nasdaq. Dat was moeilijk geweest in België.’ ©M. Scott Brauer Het Belgische biotechbedrijf Iteos Therapeutics stapte acht maanden geleden door de grote poort […]
Read Post
Consortium led by eTheRNA immunotherapies Awarded EU Commission TIGER Grant of EUR 6.9 million
Consortium led by eTheRNA immunotherapies Awarded EU Commission TIGER Grant of EUR 6.9 million Accelerate development of novel mRNA vaccine for hard-to-treat cancers Clinical trial to commence end of 2021 Niel, Belgium, 22 March 2021: eTheRNA immunotherapies NV (‘eTheRNA’), a clinical-stage company developing mRNA-based immunotherapies as off-the shelf products for the treatment of […]
Read Post
Indigo Diabetes Initiates First Clinical Study of its Continuous Glucose Monitoring Sensor
Indigo Diabetes Initiates First Clinical Study of its Continuous Glucose Monitoring Sensor Ground-breaking subcutaneous sensor aims to continuously monitor multiple metabolites including ketones in people living with diabetes BELGIUM – Ghent, March 18, 2021 – Indigo Diabetes N.V. (‘Indigo’ or the ‘Company’), a pioneering developer of medical solutions using nanophotonics, announces that its continuous multi-metabolite […]
Read Post
ExeVir Announces Close of US$50 million / EUR42 million Series A Financing
ExeVir Announces Close of US$50 million / EUR42 million Series A Financing Extends Series A with additional EUR19 million led by Fund+ Unique llama-derived VHH72-Fc antibody (XVR011) for potential treatment and prevention of Covid-19, ready to start first-in-human trials XVR011 expected to be effective against SARS-Cov-2 and importantly its rapidly spreading variants and other […]
Read Post
ExeVir Bio Announces New Publication from VIB Scientists Showing Potent and Broad Neutralizing Activity and Infection Protection Against SARS-COV, its Variants of Concern and Related Coronaviruses
ExeVir Bio Announces New Publication from VIB Scientists Showing Potent and Broad Neutralizing Activity and Infection Protection Against SARS-COV, its Variants of Concern and Related Coronaviruses • XVR011 antibody expected to be effective against SARS-Cov-2 and importantly its rapidly spreading variants and other Sarbecoviruses to emerge in future • Unique Llama-derived VHH72-Fc antibody (XVR011) for […]
Read Post
ConserV Bioscience and eTheRNA immunotherapies to Collaborate on Development of mRNA Vaccines for Infectious Diseases
ConserV Bioscience and eTheRNA immunotherapies to Collaborate on Development of mRNA Vaccines for Infectious Diseases Initial focus on development of HIV vaccine London, United Kingdom and Niel, Belgium, March 4, 2021 – ConserV Bioscience Limited (“ConserV”), a clinical-stage biotechnology company focused on developing vaccines that protect against endemic and emergent infectious diseases, and eTheRNA […]
Read Post
ONA Therapeutics appoints Mark Throsby to its Board of Directors
ONA Therapeutics appoints Mark Throsby to its Board of Directors Barcelona, Spain, March 5th, 2021: Ona Therapeutics, a company focused on the discovery and development of therapeutic biologics to treat metastatic cancer, announces today that it has appointed Dr. Mark Throsby as independent board member of its Board of Directors. Dr. Throsby is a proven […]
Read Post
Novadip Biosciences receives IND approval from the FDA for regenerative bone product NVD-003
Novadip Biosciences receives IND approval from the FDA for regenerative bone product NVD-003 – Authorization to start clinical trial in the US granted for rare paediatric bone disease Mont-Saint-Guibert, Mar 4, 2021 (GlobeNewswire) – Novadip Biosciences (“Novadip”), a clinical stage company developing treatments to regenerate impaired tissues in patients with significant unmet medical needs, today […]
Read Post
Immunic, Inc. Announces Positive Top-Line Data From Investigator- Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis
Immunic, Inc. Announces Positive Top-Line Data From Investigator- Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis – Statistically Significant Decrease in Serum Alkaline Phosphatase (ALP) Levels in the Per-Protocol Population After 24-Week IMU-838 Treatment, as Compared to Baseline – – Primary Objective of Therapeutic Benefit Achieved in 27.3% of the Patients […]
Read Post
Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial
Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial Clinical Activity of IMU-838 Confirmed Based on Multiple Secondary Endpoints, Including Clinically Meaningful Improvements in Time to Clinical Recovery and Clinical Improvement – Primary and Key Secondary Endpoints Were Not Evaluable Due to the Very […]
Read Post